Does AVR improve mortality in asymptomatic patients with high-gradient severe AS across the spectrum of LVEF?
AVR provides a mortality benefit in asymptomatic severe AS regardless of LVEF, challenging the need for an LVEF threshold for intervention.
=0.83). Conclusions Among asymptomatic patients with high-gradient severe AS, AVR was associated with a mortality benefit across the spectrum of LVEF. Our study calls into question the need of an LVEF threshold for recommending AVR in this patient population.
Perry et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: